Q-omics provides the consensus-scored GAPDHP66 profile across patient tissues and cancer cell-line models. GAPDHP66 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GAPDHP66 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GAPDHP66 RNA expression shows 7,432 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCS, KIRC, and ESCA as cancer lineages where GAPDHP66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP66 survival associations across molecular data types. GAPDHP66 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP66 RNA expression–survival associations across cancer types. High GAPDHP66 expression shows unfavorable associations in UCS, SARC, ACC and KIRC, but favorable associations in LGG and LUSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UCS as the clearest survival context for GAPDHP66 RNA expression.
This table summarizes GAPDHP66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP66 shows higher tumor expression in KIRC, HNSC, BRCA, BLCA, LUSC and LUAD. The KIRC box plot shows higher GAPDHP66 RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p < 0.001).
This table shows molecular features associated with GAPDHP66 in patient tissues and cancer cell lines. In patient samples, GAPDHP66 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
